SOLTI VALENTINE
Phase II SOLTI VALENTINE: Neoadjuvant HER3-DXd ± Letrozole for High-Risk HR+/HER2- EBC

Released: December 16, 2024

Expiration: June 15, 2025

Activity

Progress
1
Course Completed